Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial.
Shiffman ML, Cheinquer H, Berg CP, Berg T, de Figueiredo-Mendes C, Dore GJ, Ferraz ML, Mendes-Corrêa MC, Lima MP, Parise ER, Rios AM, Reuter T, Sanyal AJ, Shafran SD, Hohmann M, Tatsch F, Bakalos G, Zeuzem S. Shiffman ML, et al. Among authors: ferraz ml. Hepatol Int. 2014 Oct;8(4):517-26. doi: 10.1007/s12072-014-9555-3. Epub 2014 Jul 24. Hepatol Int. 2014. PMID: 26202757
[13C-methacetin breath test in chronic hepatitis C liver disease].
Oliveira AC, Reber M, Lanzoni V, Ferraz ML, Parise ER. Oliveira AC, et al. Among authors: ferraz ml. Arq Gastroenterol. 2006 Jan-Mar;43(1):41-4. doi: 10.1590/s0004-28032006000100011. Epub 2006 May 8. Arq Gastroenterol. 2006. PMID: 16699617 Free article. Portuguese.
Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease.
Peck-Radosavljevic M, Boletis J, Besisik F, Ferraz ML, Alric L, Samuel D, Messinger D, Tietz A, Cheinquer H. Peck-Radosavljevic M, et al. Among authors: ferraz ml. Clin Gastroenterol Hepatol. 2011 Mar;9(3):242-8. doi: 10.1016/j.cgh.2010.10.018. Epub 2010 Nov 5. Clin Gastroenterol Hepatol. 2011. PMID: 21056689 Clinical Trial.
Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis C using MALDI-TOF mass spectrometry: a pilot study.
Passos-Castilho AM, Lo Turco E, Ferraz ML, Matos C, Silva I, Parise E, Pilau E, Gozzo F, Granato C. Passos-Castilho AM, et al. Among authors: ferraz ml. J Gastrointestin Liver Dis. 2015 Mar;24(1):43-9. doi: 10.15403/jgld.2014.1121.pas. J Gastrointestin Liver Dis. 2015. PMID: 25822433 Free article.
Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.
Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML, Ahlers S, Bakalos G, Hassanein T; GUARD-C Study Group. Foster GR, et al. PLoS One. 2016 Mar 28;11(3):e0151703. doi: 10.1371/journal.pone.0151703. eCollection 2016. PLoS One. 2016. PMID: 27018988 Free PMC article. Clinical Trial.
Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach.
Benzaken AS, Girade R, Catapan E, Pereira GFM, Almeida EC, Vivaldini S, Fernandes N, Razavi H, Schmelzer J, Ferraz ML, Ferreira PRA, Pessoa MG, Martinelli A, Souto FJD, Walsh N, Mendes-Correa MC. Benzaken AS, et al. Among authors: ferraz ml. Braz J Infect Dis. 2019 May-Jun;23(3):182-190. doi: 10.1016/j.bjid.2019.04.010. Epub 2019 May 27. Braz J Infect Dis. 2019. PMID: 31145876 Free PMC article.
224 results